High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b-Reference-Cited by-同舟云学术

High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b

Published:2010-10-07 Issue:4 Volume:46 Page:501-509
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Toyoda Hidenori,Kumada Takashi,Kiriyama Seiki,Tanikawa Makoto,Hisanaga Yasuhiro,Kanamori Akira,Tada Toshifumi,Arakawa Takahiro,Fujimori Masashi,Niinomi Takuro,Ando Naoto,Yasuda Satoshi,Sakai Keisuke,Kimura Jun

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s00535-010-0328-z.pdf

Reference38 articles.

1. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.

2. Maekawa S, Enomoto N. Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J Gastroenterol. 2009;44:1009–15.

3. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology. 2007;50:361–8.

4. Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, et al. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol. 2007;81:8211–24.

5. Watanabe H, Nagayama K, Enomoto N, Itakura J, Tanabe Y, Sato C, et al. Amino acid substitutions in PKR-eIF2 phosphorylation homology domain (PePHD) of hepatitis C virus E2 protein in genotype 2a/2b and 1b in Japan and interferon efficacy. Hepatol Res. 2003;26:268–74.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics and Outcomes of HCV Genotype-1-Infected Patients Treated with Peginterferon and Ribavirin Combination Therapy with Discordant HCV Responses 4 and 12 Weeks after Starting Therapy;Intervirology;2014

2. Prevalence of Occult Hepatitis B Virus in Plasma and Peripheral Blood Mononuclear Cell Compartments of Patients WithChronic Hepatitis C Infection in Tehran-Iran;Hepatitis Monthly;2013-05-29

3. Outcome of Double-Filtration Plasmapheresis plus Interferon Treatment in Nonresponders to Pegylated Interferon plus Ribavirin Combination Therapy;Digestive Diseases;2013

4. Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin;BMC Infectious Diseases;2012-11-27

5. Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: A multicenter study;Journal of Medical Virology;2012-11-14